Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer

Journal of Molecular Diagnostics

Volumn 16, Issue 3, 2014, Pages 371-377

  Tembuyser, Lien ^a   Ligtenberg, Marjolijn J L ^b   Normanno, Nicola ^c   Delen, Sofie ^a   Van Krieken, J Han ^b   Dequeker, Elisabeth M C ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC PROCEDURE; EXTERNAL QUALITY ASSESSMENT; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; MEDICAL SOCIETY; METASTATIC COLORECTAL CANCER; MOLECULAR DIAGNOSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PRECISION MEDICINE; QUALITY CONTROL; TREATMENT RESPONSE; TUMOR INVASION; WRITTEN LANGUAGE; COLON; COLORECTAL TUMOR; GENETICS; GENOTYPE; GOOD LABORATORY PRACTICE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECTUM;

COLON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; LABORATORY PROFICIENCY TESTING; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTUM;

EID: 84898791485     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.01.003     Document Type: Article

References (30)

1. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, and G. Fountzilas et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
2. F. Loupakis, A. Ruzzo, C. Cremolini, B. Vincenzi, L. Salvatore, D. Santini, G. Masi, I. Stasi, E. Canestrari, E. Rulli, I. Floriani, K. Bencardino, N. Galluccio, V. Catalano, G. Tonini, M. Magnani, G. Fontanini, F. Basolo, A. Falcone, and F. Graziano KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 2009 715 721
3. M. Peeters, K.S. Oliner, A. Parker, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet, J.L. Van Laethem, T. Andre, J. Wiezorek, D. Reese, and S.D. Patterson Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer Clin Cancer Res 19 2013 1902 1912
4. K.S. Oliner, J.Y. Douillard, S. Siena, J. Tabernero, R.L. Burkes, and M.E. Barugel Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC) (abstract 3511) J Clin Oncol 31 Suppl 2013
5. L.S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J.L. Canon, H. Yu, and K.S. Oliner Analysis of KRAS/NRAS mutations in PEAK: a randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) (abstract 3631) J Clin Oncol 31 Suppl 2013
6. S. Stintzing, A. Jung, L. Rossius, D.P. Modest, L. Fischer von Weikersthal, T. Decker, M. Möhler, W. Scheithauer, T. Kirchner, and V. Heinemann Late Breaking Abstract: analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at the European Cancer Congress, 2013 September 27-October 1, Amsterdam, The Netherlands 2013 European Cancer Organization Amsterdam Abstract 17
7. J.H. van Krieken, N. Normanno, F. Blackhall, E. Boone, G. Botti, F. Carneiro, I. Celik, F. Ciardiello, I.A. Cree, Z.C. Deans, A. Edsjo, P.J. Groenen, O. Kamarainen, H.H. Kreipe, M.J. Ligtenberg, A. Marchetti, S. Murray, F.J. Opdam, S.D. Patterson, S. Patton, C. Pinto, E. Rouleau, E. Schuuring, S. Sterck, M. Taron, S. Tejpar, W. Timens, E. Thunnissen, P.M. van de Ven, A.G. Siebers, and E. Dequeker Guideline on the requirements of external quality assessment programs in molecular pathology Virchows Arch 462 2013 27 37
8. Organisation for Economic Co-operation and Development OECD guidelines for quality assurance in molecular genetic testing 2007 OECD Paris
9. P. Garcia-Alfonso, R. Salazar, J. Garcia-Foncillas, E. Musulen, R. Garcia-Carbonero, A. Paya, P. Perez-Segura, S. Ramon y Cajal, and S. Navarro Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) Clin Transl Oncol 14 2012 726 739
10. N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, G. Giaccone, R.B. Jenkins, D.J. Kwiatkowski, J.S. Saldivar, J. Squire, E. Thunnissen, and M. Ladanyi Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Mol Diagn 15 2013 415 453
11. J.H. van Krieken, A. Jung, T. Kirchner, F. Carneiro, R. Seruca, F.T. Bosman, P. Quirke, J.F. Flejou, T. Plato Hansen, G. de Hertogh, P. Jares, C. Langner, G. Hoefler, M. Ligtenberg, D. Tiniakos, S. Tejpar, G. Bevilacqua, and A. Ensari KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program Virchows Arch 453 2008 417 431
12. E. Thunnissen, L. Bubendorf, M. Dietel, G. Elmberger, K. Kerr, F. Lopez-Rios, H. Moch, W. Olszewski, P. Pauwels, F. Penault-Llorca, and G. Rossi EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations Virchows Arch 461 2012 245 257
13. International Organization for Standardization ISO 15189:2007 Medical laboratories - particular requirements for quality and competence 2007 ISO Geneva
14. M.L. Gulley, R.M. Braziel, K.C. Halling, E.D. His, J.A. Kant, M.N. Nikiforova, J.A. Nowak, S. Ogino, A. Oliveira, H.F. Polesky, L. Silverman, R.R. Tubbs, V.M. Van Deerlin, G.H. Vance, and J. Versalovic Clinical laboratory reports in molecular pathology Arch Pathol Lab Med 131 2007 852 863
15. International Organization for Standardization ISO 15189:2012 Medical laboratories - particular requirements for quality and competence 2012 ISO Geneva
16. V. Heinemann, J.Y. Douillard, M. Ducreux, and M. Peeters Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action Cancer Treat Rev 39 2013 592 601
17. L. Vecchione, B. Jacobs, N. Normanno, F. Ciardiello, and S. Tejpar EGFR-targeted therapy Exp Cell Res 317 2011 2765 2771
18. S. Edkins, S. O'Meara, A. Parker, C. Stevens, M. Reis, S. Jones, C. Greenman, H. Davies, G. Dalgliesh, S. Forbes, C. Hunter, R. Smith, P. Stephens, P. Goldstraw, A. Nicholson, T.L. Chan, V.E. Velculescu, S.T. Yuen, S.Y. Leung, M.R. Stratton, and P.A. Futreal Recurrent KRAS codon 146 mutations in human colorectal cancer Cancer Biol Ther 5 2006 928 932
19. N. Normanno, S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem, and F. Ciardiello Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
20. A. Igbokwe, and D.H. Lopez-Terrada Molecular testing of solid tumors Arch Pathol Lab Med 135 2011 67 82
21. C.P. Vaughn, S.D. Zobell, L.V. Furtado, C.L. Baker, and W.S. Samowitz Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer Genes Chromosomes Cancer 50 2011 307 312
22. C. Meldrum, M.A. Doyle, and R.W. Tothill Next-generation sequencing for cancer diagnostics: a practical perspective Clin Biochem Rev 32 2011 177 195
23. P. Garrido, J. de Castro, A. Concha, E. Felip, D. Isla, F. Lopez-Rios, L. Paz-Ares, J. Ramirez, J. Sanz, and J.J. Gomez Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) Clin Transl Oncol 14 2012 338 349
24. J.S. Ross Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective Arch Pathol Lab Med 136 2012 1298 1307
25. D.Z. Chang, V. Kumar, Y. Ma, K. Li, and S. Kopetz Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy J Hematol Oncol 2 2009 18
26. J.Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocakova, P. Ruff, M. Blasinska-Morawiec, M. Smakal, J.L. Canon, M. Rother, K.S. Oliner, M. Wolf, and J. Gansert Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
27. Z.C. Deans, N. Bilbe, B. O'Sullivan, L.P. Lazarou, D.G. de Castro, S. Parry, A. Dodson, P. Taniere, C. Clark, and R. Butler Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment J Clin Pathol 66 2013 319 325
28. E. Bellon, M.J. Ligtenberg, S. Tejpar, K. Cox, G. de Hertogh, K. de Stricker, A. Edsjo, V. Gorgoulis, G. Hofler, A. Jung, A. Kotsinas, P. Laurent-Puig, F. Lopez-Rios, T.P. Hansen, E. Rouleau, P. Vandenberghe, J.J. van Krieken, and E. Dequeker External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds Oncologist 16 2011 467 478
29. N. Normanno, C. Pinto, F. Castiglione, A. Bardelli, M. Gambacorta, G. Botti, O. Nappi, S. Siena, F. Ciardiello, G. Taddei, and A. Marchetti KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment PLoS One 6 2011 e29146
30. S. Berwouts, E. Girodon, M. Schwarz, M. Stuhrmann, M.A. Morris, and E. Dequeker Improvement of interpretation in cystic fibrosis clinical laboratory reports: longitudinal analysis of external quality assessment data Eur J Hum Genet 20 2012 1209 1215